-
1
-
-
77951755278
-
Pancreatic cancer
-
Hidalgo, M. Pancreatic cancer. N. Engl. J. Med. 362, 1605-1617 (2010
-
(2010)
N. Engl. J. Med
, vol.362
, pp. 1605-1617
-
-
Hidalgo, M.1
-
2
-
-
84905190648
-
European cancer mortality predictions for the year 2014
-
Malvezzi, M., Bertuccio, P., Levi, F., La Vecchia, C. & Negri, E. European cancer mortality predictions for the year 2014. Ann. Oncol. 25, 1650-1656 (2014
-
(2014)
Ann. Oncol
, vol.25
, pp. 1650-1656
-
-
Malvezzi, M.1
Bertuccio, P.2
Levi, F.3
La Vecchia, C.4
Negri, E.5
-
3
-
-
84920837701
-
Cancer statistics 2015
-
Siegel, R.L., Miller, K.D. & Jemal, A. Cancer statistics, 2015. CA Cancer J. Clin. 65, 5-29 (2015
-
(2015)
CA Cancer J. Clin
, vol.65
, pp. 5-29
-
-
Siegel, R.L.1
Miller, K.D.2
Jemal, A.3
-
4
-
-
8244254377
-
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
-
Burris, H.A. III et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403-2413 (1997
-
(1997)
J. Clin. Oncol
, vol.15
, pp. 2403-2413
-
-
Burris, H.A.1
-
5
-
-
79955921754
-
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
-
Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817-1825 (2011
-
(2011)
N. Engl. J. Med
, vol.364
, pp. 1817-1825
-
-
Conroy, T.1
-
6
-
-
84886741654
-
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine
-
Von Hoff, D.D. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369, 1691-1703 (2013
-
(2013)
N. Engl. J. Med
, vol.369
, pp. 1691-1703
-
-
Von Hoff, D.D.1
-
7
-
-
80051700067
-
Pancreatic cancer
-
Vincent, A., Herman, J., Schulick, R., Hruban, R.H. & Goggins, M. Pancreatic cancer. Lancet 378, 607-620 (2011
-
(2011)
Lancet
, vol.378
, pp. 607-620
-
-
Vincent, A.1
Herman, J.2
Schulick, R.3
Hruban, R.H.4
Goggins, M.5
-
8
-
-
34249933404
-
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase 3 trial of the National Cancer Institute of Canada clinical trials group
-
Moore, M.J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase 3 trial of the National Cancer Institute of Canada clinical trials group. J. Clin. Oncol. 25, 1960-1966 (2007
-
(2007)
J. Clin. Oncol
, vol.25
, pp. 1960-1966
-
-
Moore, M.J.1
-
9
-
-
84944073483
-
Subtyping pancreatic cancer
-
Biankin, A.V. & Maitra, A. Subtyping pancreatic cancer. Cancer Cell 28, 411-413 (2015
-
(2015)
Cancer Cell
, vol.28
, pp. 411-413
-
-
Biankin, A.V.1
Maitra, A.2
-
10
-
-
84965188725
-
Identifying molecular subtypes related to clinicopathologic factors in pancreatic cancer
-
Kim, S. et al. Identifying molecular subtypes related to clinicopathologic factors in pancreatic cancer. Biomed. Eng. Online 13, S5 (2014
-
(2014)
Biomed. Eng. Online
, vol.13
, pp. S5
-
-
Kim, S.1
-
11
-
-
79953756460
-
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
-
Collisson, E.A. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500-503 (2011
-
(2011)
Nat. Med
, vol.17
, pp. 500-503
-
-
Collisson, E.A.1
-
12
-
-
84855945142
-
-
2nd edn. (ed. McQueen, C.A.) 9.43-9.76 Elsevier Ltd., Oxford
-
Guengrich, F.P. in Comprehensive Toxicology 2nd edn. (ed. McQueen, C.A.) 9.43-9.76 (Elsevier Ltd., Oxford, 2010
-
(2010)
Comprehensive Toxicology
-
-
Guengrich, F.P.1
-
13
-
-
18644380835
-
Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: Focus on tamoxifen, paclitaxel and imatinib metabolism
-
Rochat, B. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin. Pharmacokinet. 44, 349-366 (2005
-
(2005)
Clin. Pharmacokinet
, vol.44
, pp. 349-366
-
-
Rochat, B.1
-
14
-
-
34249930470
-
Targeting cytochrome P450 enzymes: A new approach in anticancer drug development
-
Bruno, R.D. & Njar, V.C.O. Targeting cytochrome P450 enzymes: a new approach in anticancer drug development. Bioorg. Med. Chem. 15, 5047-5060 (2007
-
(2007)
Bioorg. Med. Chem
, vol.15
, pp. 5047-5060
-
-
Bruno, R.D.1
Njar, V.C.O.2
-
15
-
-
37349067079
-
Drug metabolism by tumors: Its nature, relevance and therapeutic implications
-
Michael, M. & Doherty, M.M. Drug metabolism by tumors: its nature, relevance and therapeutic implications. Expert Opin. Drug Metab. Toxicol. 3, 783-803 (2007
-
(2007)
Expert Opin. Drug Metab. Toxicol
, vol.3
, pp. 783-803
-
-
Michael, M.1
Doherty, M.M.2
-
16
-
-
84887425166
-
Evolution and dynamics of pancreatic cancer progression
-
Yachida, S. & Iacobuzio-Donahue, C.A. Evolution and dynamics of pancreatic cancer progression. Oncogene 32, 5253-5260 (2013
-
(2013)
Oncogene
, vol.32
, pp. 5253-5260
-
-
Yachida, S.1
Iacobuzio-Donahue, C.A.2
-
17
-
-
84869091997
-
Pancreatic cancer genomes reveal aberrations in axon-guidance pathway genes
-
Biankin, A.V. et al. Pancreatic cancer genomes reveal aberrations in axon-guidance pathway genes. Nature 491, 399-405 (2012
-
(2012)
Nature
, vol.491
, pp. 399-405
-
-
Biankin, A.V.1
-
18
-
-
52149123619
-
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
-
Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008
-
(2008)
Science
, vol.321
, pp. 1801-1806
-
-
Jones, S.1
-
19
-
-
78650034777
-
Toward a knowledge-based Human Protein Atlas
-
Uhlen, M. et al. Toward a knowledge-based Human Protein Atlas. Nat. Biotechnol. 28, 1248-1250 (2010
-
(2010)
Nat. Biotechnol
, vol.28
, pp. 1248-1250
-
-
Uhlen, M.1
-
20
-
-
84883670305
-
Recent progress in pancreatic cancer
-
Wolfgang, C.L. et al. Recent progress in pancreatic cancer. CA Cancer J. Clin. 63, 318-348 (2013
-
(2013)
CA Cancer J. Clin
, vol.63
, pp. 318-348
-
-
Wolfgang, C.L.1
-
21
-
-
47549109327
-
-
Tumors of the Pancreas 6th edn Washington, D.C.
-
Hruban, R.H., Pitman, M.B. & Klimstra, D.S. Tumors of the Pancreas 6th edn. (American Registry of Pathology, Washington, D.C., 2007
-
(2007)
American Registry of Pathology
-
-
Hruban, R.H.1
Pitman, M.B.2
Klimstra, D.S.3
-
22
-
-
84880921289
-
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors
-
Hong, D.S. et al. A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Invest. New Drugs 31, 918-926 (2013
-
(2013)
Invest. New Drugs
, vol.31
, pp. 918-926
-
-
Hong, D.S.1
-
23
-
-
84894059672
-
Src inhibition is still a relevant target in pancreatic cancer
-
George, T.J. Jr., Trevino, J.G. & Liu, C. Src inhibition is still a relevant target in pancreatic cancer. Oncologist 19, 211 (2014
-
(2014)
Oncologist
, vol.19
, pp. 211
-
-
George, T.J.1
Trevino, J.G.2
Liu, C.3
-
24
-
-
33644647192
-
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model
-
Trevino, J.G. et al. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am. J. Pathol. 168, 962-972 (2006
-
(2006)
Am. J. Pathol
, vol.168
, pp. 962-972
-
-
Trevino, J.G.1
-
25
-
-
33344461165
-
Metabolism and excretion of erlotinib, a small-molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers
-
Ling, J. et al. Metabolism and excretion of erlotinib, a small-molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab. Dispos. 34, 420-426 (2006
-
(2006)
Drug Metab. Dispos
, vol.34
, pp. 420-426
-
-
Ling, J.1
-
26
-
-
46449088111
-
Metabolism and disposition of dasatinib after oral administration to humans
-
Christopher, L.J. et al. Metabolism and disposition of dasatinib after oral administration to humans. Drug Metab. Dispos. 36, 1357-1364 (2008
-
(2008)
Drug Metab. Dispos
, vol.36
, pp. 1357-1364
-
-
Christopher, L.J.1
-
27
-
-
34250694236
-
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes
-
Li, J., Zhao, M., He, P., Hidalgo, M. & Baker, S.D. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin. Cancer Res. 13, 3731-3737 (2007
-
(2007)
Clin. Cancer Res
, vol.13
, pp. 3731-3737
-
-
Li, J.1
Zhao, M.2
He, P.3
Hidalgo, M.4
Baker, S.D.5
-
28
-
-
50049093958
-
Identification of the human enzymes involved in the oxidative metabolism of dasatinib: An effective approach for determining metabolite formation kinetics
-
Wang, L. et al. Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab. Dispos. 36, 1828-1839 (2008
-
(2008)
Drug Metab. Dispos
, vol.36
, pp. 1828-1839
-
-
Wang, L.1
-
29
-
-
84859169877
-
The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity
-
Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity. Nature 483, 603-607 (2012
-
(2012)
Nature
, vol.483
, pp. 603-607
-
-
Barretina, J.1
-
30
-
-
84855945142
-
-
2nd edn. (ed. McQueen C.A.) 4.9-4.29 Elsevier, Oxford
-
Ding, X. & Zhang, Q.Y. in Comprehensive Toxicology 2nd edn. (ed. McQueen, C.A.) 4.9-4.29 (Elsevier, Oxford, 2010
-
(2010)
Comprehensive Toxicology
-
-
Ding, X.1
Zhang, Q.Y.2
-
31
-
-
69949151386
-
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors
-
Jänne, P.A., Gray, N. & Settleman, J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat. Rev. Drug Discov. 8, 709-723 (2009
-
(2009)
Nat. Rev. Drug Discov
, vol.8
, pp. 709-723
-
-
Jänne, P.A.1
Gray, N.2
Settleman, J.3
-
32
-
-
0032005259
-
Metabolism of irinotecan (CPT-11) by human hepatic microsomes: Participation of cytochrome P450 3A and drug interactions
-
Haaz, M.C., Rivory, L., Riché, C., Vernillet, L. & Robert, J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P450 3A and drug interactions. Cancer Res. 58, 468-472 (1998
-
(1998)
Cancer Res
, vol.58
, pp. 468-472
-
-
Haaz, M.C.1
Rivory, L.2
Riché, C.3
Vernillet, L.4
Robert, J.5
-
34
-
-
4644231469
-
The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR
-
Burk, O. et al. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J. Biol. Chem. 279, 38379-38385 (2004
-
(2004)
J. Biol. Chem
, vol.279
, pp. 38379-38385
-
-
Burk, O.1
-
36
-
-
0037327003
-
The orphan nuclear receptor HNF-4? Determines PXR- and CAR-mediated xenobiotic induction of CYP3A4
-
Tirona, R.G. et al. The orphan nuclear receptor HNF-4? determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat. Med. 9, 220-224 (2003
-
(2003)
Nat. Med
, vol.9
, pp. 220-224
-
-
Tirona, R.G.1
-
38
-
-
66049149024
-
Identification of an endogenous ligand bound to a native orphan nuclear receptor
-
Yuan, X. et al. Identification of an endogenous ligand bound to a native orphan nuclear receptor. PLoS One 4, e5609 (2009
-
(2009)
PLoS One
, vol.4
, pp. e5609
-
-
Yuan, X.1
-
39
-
-
84877934154
-
Pregnane X receptor (PXR) at the crossroads of human metabolism and disease
-
Koutsounas, I., Theocharis, S., Patsouris, E. & Giaginis, C. Pregnane X receptor (PXR) at the crossroads of human metabolism and disease. Curr. Drug Metab. 14, 341-350 (2013
-
(2013)
Curr. Drug Metab
, vol.14
, pp. 341-350
-
-
Koutsounas, I.1
Theocharis, S.2
Patsouris, E.3
Giaginis, C.4
-
40
-
-
84878862550
-
3D structures and ligand specificities of nuclear xenobiotic receptors CAR PXR and VDR
-
Wu, B., Li, S. & Dong, D. 3D structures and ligand specificities of nuclear xenobiotic receptors CAR, PXR and VDR. Drug Discov. Today 18, 574-581 (2013
-
(2013)
Drug Discov. Today
, vol.18
, pp. 574-581
-
-
Wu, B.1
Li, S.2
Dong, D.3
-
41
-
-
16644379769
-
Tumoral drug metabolism: Overview and its implications for cancer therapy
-
Michael, M. & Doherty, M.M. Tumoral drug metabolism: overview and its implications for cancer therapy. J. Clin. Oncol. 23, 205-229 (2005
-
(2005)
J. Clin. Oncol
, vol.23
, pp. 205-229
-
-
Michael, M.1
Doherty, M.M.2
-
42
-
-
41549114526
-
Xenobiotic-induced transcriptional regulation of xenobiotic-metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues
-
Pavek, P. & Dvorak, Z. Xenobiotic-induced transcriptional regulation of xenobiotic-metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. Curr. Drug Metab. 9, 129-143 (2008
-
(2008)
Curr. Drug Metab
, vol.9
, pp. 129-143
-
-
Pavek, P.1
Dvorak, Z.2
-
43
-
-
0037478407
-
Human extrahepatic cytochromes P450: Function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts
-
Ding, X. & Kaminsky, L.S. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 43, 149-173 (2003
-
(2003)
Annu. Rev. Pharmacol. Toxicol
, vol.43
, pp. 149-173
-
-
Ding, X.1
Kaminsky, L.S.2
-
44
-
-
27144434397
-
Profiling cytochrome P450 expression in ovarian cancer: Identification of prognostic markers
-
Downie, D. et al. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin. Cancer Res. 11, 7369-7375 (2005
-
(2005)
Clin. Cancer Res
, vol.11
, pp. 7369-7375
-
-
Downie, D.1
-
45
-
-
0034046572
-
Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line
-
Hukkanen, J. et al. Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line. Am. J. Respir. Cell Mol. Biol. 22, 360-366 (2000
-
(2000)
Am. J. Respir. Cell Mol. Biol
, vol.22
, pp. 360-366
-
-
Hukkanen, J.1
-
46
-
-
77955807020
-
Profiling the expression of cytochrome P450 in breast cancer
-
Murray, G.I., Patimalla, S., Stewart, K.N., Miller, I.D. & Heys, S.D. Profiling the expression of cytochrome P450 in breast cancer. Histopathology 57, 202-211 (2010
-
(2010)
Histopathology
, vol.57
, pp. 202-211
-
-
Murray, G.I.1
Patimalla, S.2
Stewart, K.N.3
Miller, I.D.4
Heys, S.D.5
-
47
-
-
34047176473
-
Cytochrome P450 levels are altered in patients with esophageal squamous-cell carcinoma
-
Bergheim, I. et al. Cytochrome P450 levels are altered in patients with esophageal squamous-cell carcinoma. World J. Gastroenterol. 13, 997-1002 (2007
-
(2007)
World J. Gastroenterol
, vol.13
, pp. 997-1002
-
-
Bergheim, I.1
-
48
-
-
0038352146
-
Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma
-
Dhaini, H.R. et al. Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J. Clin. Oncol. 21, 2481-2485 (2003
-
(2003)
J. Clin. Oncol
, vol.21
, pp. 2481-2485
-
-
Dhaini, H.R.1
-
49
-
-
1942452881
-
Expression of cytochrome P450 in lung tumor
-
Gharavi, N. & El-Kadi, A.O.S. Expression of cytochrome P450 in lung tumor. Curr. Drug Metab. 5, 203-210 (2004
-
(2004)
Curr. Drug Metab
, vol.5
, pp. 203-210
-
-
Gharavi, N.1
El-Kadi, A.O.S.2
-
50
-
-
4644346406
-
Cytochrome P450 CYP1B1 activity in renal cell carcinoma
-
McFadyen, M.C., Melvin, W.T. & Murray, G.I. Cytochrome P450 CYP1B1 activity in renal cell carcinoma. Br. J. Cancer 91, 966-971 (2004
-
(2004)
Br. J. Cancer
, vol.91
, pp. 966-971
-
-
McFadyen, M.C.1
Melvin, W.T.2
Murray, G.I.3
-
51
-
-
2442679411
-
Expression of cytochrome P450 in tumor tissues and its association with cancer development
-
Oyama, T. et al. Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front. Biosci. 9, 1967-1976 (2004
-
(2004)
Front. Biosci
, vol.9
, pp. 1967-1976
-
-
Oyama, T.1
-
52
-
-
84869426063
-
Cytochrome P450 in non-small-cell lung cancer related to exogenous chemical metabolism
-
Oyama, T. et al. Cytochrome P450 in non-small-cell lung cancer related to exogenous chemical metabolism. Front. Biosci. (Schol. Ed.) 4, 1539-1546 (2012
-
(2012)
Front. Biosci. (Schol. Ed.)
, vol.4
, pp. 1539-1546
-
-
Oyama, T.1
-
53
-
-
1642353685
-
CYP3A4 CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes
-
Schmidt, R. et al. CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes. Br. J. Cancer 90, 911-916 (2004
-
(2004)
Br. J. Cancer
, vol.90
, pp. 911-916
-
-
Schmidt, R.1
-
54
-
-
76749157232
-
Expressions of cytochrome P450 UDP-glucuronosyltranferase and transporter genes in monolayer carcinoma cells change in subcutaneous tumors grown as xenografts in immunodeficient nude mice
-
Sugawara, M. et al. Expressions of cytochrome P450, UDP-glucuronosyltranferase and transporter genes in monolayer carcinoma cells change in subcutaneous tumors grown as xenografts in immunodeficient nude mice. Drug Metab. Dispos. 38, 526-533 (2010
-
(2010)
Drug Metab. Dispos
, vol.38
, pp. 526-533
-
-
Sugawara, M.1
-
55
-
-
79959868909
-
Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells
-
Basseville, A. et al. Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells. Mol. Cancer 10, 80 (2011
-
(2011)
Mol. Cancer
, vol.10
, pp. 80
-
-
Basseville, A.1
-
56
-
-
0035071598
-
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
-
Kuehl, P. et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391 (2001
-
(2001)
Nat. Genet
, vol.27
, pp. 383-391
-
-
Kuehl, P.1
-
57
-
-
0037518214
-
Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism
-
Westlind-Johnsson, A. et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab. Dispos. 31, 755-761 (2003
-
(2003)
Drug Metab. Dispos
, vol.31
, pp. 755-761
-
-
Westlind-Johnsson, A.1
-
58
-
-
84865161972
-
Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs
-
Walsky, R.L. et al. Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs. Drug Metab. Dispos. 40, 1686-1697 (2012
-
(2012)
Drug Metab. Dispos
, vol.40
, pp. 1686-1697
-
-
Walsky, R.L.1
-
59
-
-
51649111430
-
Single-cell cloning of colon cancer stem cells reveals a multilineage differentiation capacity
-
Vermeulen, L. et al. Single-cell cloning of colon cancer stem cells reveals a multilineage differentiation capacity. Proc. Natl. Acad. Sci. USA 105, 13427-13432 (2008
-
(2008)
Proc. Natl. Acad. Sci. USA
, vol.105
, pp. 13427-13432
-
-
Vermeulen, L.1
-
60
-
-
27344435774
-
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
-
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005
-
(2005)
Proc. Natl. Acad. Sci. USA
, vol.102
, pp. 15545-15550
-
-
Subramanian, A.1
-
61
-
-
79961123152
-
RSEM accurate transcript quantification from RNA-seq data with or without a reference genome
-
Li, B. & Dewey, C.N. RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011
-
(2011)
BMC Bioinformatics
, vol.12
, pp. 323
-
-
Li, B.1
Dewey, C.N.2
-
62
-
-
84859098571
-
The sva package for removing batch effects and other unwanted variation in high-throughput experiments
-
Leek, J.T., Johnson, W.E., Parker, H.S., Jaffe, A.E. & Storey, J.D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882-883 (2012
-
(2012)
Bioinformatics
, vol.28
, pp. 882-883
-
-
Leek, J.T.1
Johnson, W.E.2
Parker, H.S.3
Jaffe, A.E.4
Storey, J.D.5
-
63
-
-
84907704976
-
Removing batch effects for prediction problems with frozen surrogate variable analysis
-
Parker, H.S., Corrada Bravo, H. & Leek, J.T. Removing batch effects for prediction problems with frozen surrogate variable analysis. PeerJ 2, e561 (2014
-
(2014)
PeerJ
, vol.2
, pp. e561
-
-
Parker, H.S.1
Corrada Bravo, H.2
Leek, J.T.3
-
64
-
-
11244346557
-
Variance stabilization applied to microarray data calibration and to the quantification of differential expression
-
Huber, W., von Heydebreck, A., Sültmann, H., Poustka, A. & Vingron, M. Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 18 (suppl. 1), S96-S104 (2002
-
(2002)
Bioinformatics
, vol.18
, pp. S96-S104
-
-
Huber, W.1
Von Heydebreck, A.2
Sültmann, H.3
Poustka, A.4
Vingron, M.5
-
65
-
-
0035942271
-
Significance analysis of microarrays applied to the ionizing radiation response
-
Tusher, V.G., Tibshirani, R. & Chu, G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA 98, 5116-5121 (2001
-
(2001)
Proc. Natl. Acad. Sci. USA
, vol.98
, pp. 5116-5121
-
-
Tusher, V.G.1
Tibshirani, R.2
Chu, G.3
-
66
-
-
84884764745
-
High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma
-
Stenzinger, A. et al. High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma. BMC Cancer 13, 450 (2013
-
(2013)
BMC Cancer
, vol.13
, pp. 450
-
-
Stenzinger, A.1
|